Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Journal of Clinical Oncology|2023Cited by 109
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort studyGiulia Maggioni, Uwe Platzbecker, Matteo Bersanelli et al.|The Lancet Haematology|2022Cited by 34
Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndromeCarmelo Gurnari, Maria Teresa Voso, Paola Triggianese et al.|British Journal of Haematology|2024Cited by 10
<i>JAK2</i> is a critical therapeutic target in <scp>VEXAS</scp> syndrome treated with ruxolitinibAndrea Ceccardi, Gabriele Zoppoli, Martina Dameri et al.|British Journal of Haematology|2025Cited by 8